Abstract
Multiple lines of evidence suggest that hypofunction of glutamatergic neurotransmission via N-methyl-Daspartate (NMDA) receptors might be implicated in the pathophysiology of schizophrenia. The NMDA receptor hypofunction hypothesis of schizophrenia suggests that increasing NMDA receptor function via pharmacological manipulation could provide a potential new strategy for the management of schizophrenia. Currently, the glycine modulatory sites on NMDA receptors present the most attractive therapeutic targets for the treatment of schizophrenia. One means of enhancing NMDA receptor neurotransmission is to increase the availability of the obligatory co-agonist glycine at modulatory sites through the inhibition of glycine transporter-1 (GlyT-1) on glial cells. With the aim of treating schizophrenia, a number of pharmaceutical industries have developed novel and selective GlyT-1 inhibitors, and recent studies have demonstrated that the GlyT-1 inhibitor sarcosine (N-methyl glycine) could be a potential drug. The present review considers GlyT-1 inhibitors as novel drugs for the treatment of schizophrenia.
Keywords: Schizophrenia, NMDA receptor, glutamate, glycine, transporter, glia
Central Nervous System Agents in Medicinal Chemistry
Title: Glycine Transporter-1 Inhibitors as Novel Therapeutic Drugs for Schizophrenia
Volume: 7 Issue: 3
Author(s): Kenji Hashimoto
Affiliation:
Keywords: Schizophrenia, NMDA receptor, glutamate, glycine, transporter, glia
Abstract: Multiple lines of evidence suggest that hypofunction of glutamatergic neurotransmission via N-methyl-Daspartate (NMDA) receptors might be implicated in the pathophysiology of schizophrenia. The NMDA receptor hypofunction hypothesis of schizophrenia suggests that increasing NMDA receptor function via pharmacological manipulation could provide a potential new strategy for the management of schizophrenia. Currently, the glycine modulatory sites on NMDA receptors present the most attractive therapeutic targets for the treatment of schizophrenia. One means of enhancing NMDA receptor neurotransmission is to increase the availability of the obligatory co-agonist glycine at modulatory sites through the inhibition of glycine transporter-1 (GlyT-1) on glial cells. With the aim of treating schizophrenia, a number of pharmaceutical industries have developed novel and selective GlyT-1 inhibitors, and recent studies have demonstrated that the GlyT-1 inhibitor sarcosine (N-methyl glycine) could be a potential drug. The present review considers GlyT-1 inhibitors as novel drugs for the treatment of schizophrenia.
Export Options
About this article
Cite this article as:
Hashimoto Kenji, Glycine Transporter-1 Inhibitors as Novel Therapeutic Drugs for Schizophrenia, Central Nervous System Agents in Medicinal Chemistry 2007; 7 (3) . https://dx.doi.org/10.2174/187152407781669161
DOI https://dx.doi.org/10.2174/187152407781669161 |
Print ISSN 1871-5249 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6166 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Sleep and Circadian Profiles of Bipolar Disorder: From Chronobiology to Novel Therapeutic Strategies
Current Psychiatry Reviews A Review of the Three-Dimensional Cell Culture Technique: Approaches, Advantages and Applications
Current Stem Cell Research & Therapy Mitochondria: “Mood Altering Organelles” that Impact Disease Throughout the Nervous System
Current Neurovascular Research Allergic Asthma: A Summary from Genetic Basis, Mouse Studies, to Diagnosis and Treatment
Current Pharmaceutical Design Major CYP450 Polymorphism among Saudi Patients
Drug Metabolism Letters Educating Scientists in Translational and Entrepreneurial Medicine: Unmet Needs and Challenges
Technology Transfer and Entrepreneurship (Discontinued) Drug Treatment of Obesity: Established and Emerging Therapies
Mini-Reviews in Medicinal Chemistry Cessation of HIV-1 Transcription by Inhibiting Regulatory Protein Rev- Mediated RNA Transport
Current HIV Research Controlling Apoptosis by Inhibition of Caspases
Current Medicinal Chemistry Editorial [Hot Topic: Drug Targets in Alzheimers Disease (Executive Editors: G. Munch and G. Stuchbury)]
Current Pharmaceutical Design Response to Treatment with Placebo, Medication or Psychotherapy in Severe Non- Psychotic Major Depressive Disorder
Current Psychiatry Reviews Temporal Progression of Kainic Acid Induced Changes in Vascular Laminin Expression in Rat Brain with Neuronal and Glial Correlates
Current Neurovascular Research Physical Activity and Diabetic Cardiomyopathy: Myocardial Adaptation Depending on Exercise Load
Current Diabetes Reviews The Role of the Endothelium in Premature Atherosclerosis: Molecular Mechanisms
Current Medicinal Chemistry mTOR, a Potential Target to Treat Autism Spectrum Disorder
CNS & Neurological Disorders - Drug Targets Polymeric Nanomicelles of Soluplus® as a Strategy for Enhancing the Solubility, Bioavailability and Efficacy of Poorly Soluble Active Compounds
Current Nanomedicine The Role of Aβ Peptides in Alzheimers Disease
Protein & Peptide Letters PUFA for Human Health: Diet or Supplementation?
Current Pharmaceutical Design Roles of Biogenic Amines in Intestinal Signaling
Current Protein & Peptide Science Hemodynamic Assessment and In vivo Catabolism of Adenosine 5’-triphosphate in Doxorubicin or Isoproterenol-induced Cardiovascular Toxicity
Drug Metabolism Letters